bpc-157 fda warning october 2025 On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Letter to Platinum Biologics LLC for marketing umbilical‑cord‑derived products including exosome products (“NanoEx” & “Nano Xsomes”) without approval FDA's Overreach on Compounded Peptides

JAMA, 327 (2), 138150

Ultimately, this model aims to drive competition among similar specialists with a targeted assessment of their performance relative to their peers in the treatment of a specific chronic condition and protect taxpayers by reducing low-value services by holding specialists accountable for the cost of services clinically related to their role in managing care

Those services were selected as part of the scope of longitudinal heart failure chronic condition management in consultation with specialty societies and practices

We never test our own products the testing lab is a separate entity with no financial relationship to Pepta Labs

After consideration of public comments, for CY 2026, we are finalizing our proposal not to nominate ( CPT codes 96920, 92921, and 96922 as potentially misvalued

With our expert medical guidance, you can get to the root of hormonal imbalances contributing to your symptoms and start looking and feeling like your younger self again